CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (144,187)	$ (128,832)	$ (52,788)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	39,777	31,848	14,812
Amortization of inventory step-up	901	9,826	0
Allowance for credit losses and inventory reserves	3,888	892	1,586
Share-based compensation	67,240	43,710	41,885
Amortization of discount and cost of issuance of debt	1,172	997	417
Asset impairment in relation to restructuring	998	0	0
Gain from change in fair value of warrants	0	(7,066)	(55,069)
(Gain) loss from change in fair value of contingent considerations and acquisition-related holdbacks	(29,041)	2,985	(9,468)
(Gain) loss from change in fair value of currency forward contract	1,650	850	(208)
Deferred tax liabilities	(5,366)	(4,198)	(2,002)
Amortization of right-of-use assets	3,284	2,737	1,949
Other	0	14	230
Changes in operating assets and liabilities:
Accounts receivable	9,592	(32,199)	(12,161)
Inventory	(16,967)	(5,785)	(4,299)
Accounts payable	10,991	(1,697)	7,419
Accrued expenses and other current liabilities	3,539	(3,211)	1,364
Accrued payroll liabilities	(289)	(562)	528
Prepaid, other current and noncurrent assets	963	(10,298)	(8,175)
Operating lease liabilities	(2,934)	(2,500)	(1,488)
Other long-term liabilities	(3,812)	(1,896)	(1,278)
Net cash used in operating activities	(58,601)	(104,385)	(76,746)
Cash flows from investing activities:
Purchases of property and equipment	(14,337)	(12,752)	(7,568)
Payments for acquired software license	(1,722)	0	0
Business combinations, net of cash acquired	(3,200)	(94,990)	(8,705)
Net cash used in investing activities	(19,259)	(107,742)	(16,273)
Cash flows from financing activities:
Proceeds from issuance of common stock/At-the-market offering	19,847	53,136	17,203
Offering costs for the issuance of common stock/At-the-market offering	(428)	(1,138)	(379)
Proceeds from Wuxi Capital Raise	0	0	41,861
Issuance costs related to Wuxi Capital Raise	0	0	(39)
Wuxi EIP capital paid in	0	12,346	0
2029 convertible note capped call transactions	(23,380)	0	0
Proceeds from issuance of debt obligations	230,361	1,148	161,507
Issuance and debt discount costs related to debt obligations	(667)	0	(5,374)
Repurchase of common stock	0	0	(7,404)
Payments on debt obligations	(7,965)	(12,831)	(2,158)
Payments on financed software	(5,451)	(9,125)	(4,161)
Deferred payments on business combination	(3,036)	0	(8,500)
Proceeds from exercise of stock options	53	31	103
Net cash provided by financing activities	209,334	43,567	192,659
Effect of exchange rate changes on cash, and cash equivalents	1,396	(1,641)	2,774
Net increase (decrease) in cash and cash equivalents	132,870	(170,201)	102,415
Cash, cash equivalents, and restricted cash at beginning of period	151,678	321,879	219,464
Cash, cash equivalents, and restricted cash at end of period	284,548	151,678	321,879
Supplemental disclosure of cash flow information:
Cash paid for interest	7,435	7,421	376
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment, accrued but not paid	352	(300)	1,464
Fair value of common stock issued for investment in Expedera	3,428	0	0
Fair value of common stock issued for business combination	0	128,181	0
Fair value of common stock issued to satisfy contingent considerations and acquisition-related holdbacks	64,148	5,159	0
Fair value of common stock issuable for business combination	0	23,479	0
Contingent consideration for business combination	4,599	81,745	7,836
Accrual for purchase consideration for business combination	$ 800	$ 800	$ 9,674